BR112013009624A2 - uso de derivados de 2-carboxamida cicloamino ureia no tratamento de doenças dependemtes de egfr pu doenças que tenham adquirido resistência a agentes que tenham como alvo membros da família egfr - Google Patents
uso de derivados de 2-carboxamida cicloamino ureia no tratamento de doenças dependemtes de egfr pu doenças que tenham adquirido resistência a agentes que tenham como alvo membros da família egfrInfo
- Publication number
- BR112013009624A2 BR112013009624A2 BR112013009624A BR112013009624A BR112013009624A2 BR 112013009624 A2 BR112013009624 A2 BR 112013009624A2 BR 112013009624 A BR112013009624 A BR 112013009624A BR 112013009624 A BR112013009624 A BR 112013009624A BR 112013009624 A2 BR112013009624 A2 BR 112013009624A2
- Authority
- BR
- Brazil
- Prior art keywords
- diseases
- egfr
- treatment
- acquired resistance
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
uso de derivados de 2-carboxamida cicloalmico ureia no tratamento de doenças depemdemtes de egfr pu doenças que tenham adquirido resistência a agentes que tenham como alvo membros da família egfr. a presente invenção refere-se ao uso de compostos de fórmula (i): no tratamento de doenças dependentes do receptor de fator do crescimento epidérmico (egfr) ou doenças que tenham adiquirido resistência a agentes que tenham como alvo membros da família egfr, uso dos ditos compostos para a fabricação de composições farmacêuticas para o tratamento das ditas doenças, combinações dos ditos compostos com moduladores de egfr para o dito uso, métodos de tratamento das ditas doenças com os ditos compostos, e preparações farmacêuticas para o trata mento das diras doenças, compreendendo os ditos compostos isoladamente ou em combinação, particularmente com um modulador de egfr.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41111710P | 2010-11-08 | 2010-11-08 | |
PCT/EP2011/069522 WO2012062694A1 (en) | 2010-11-08 | 2011-11-07 | Use of 2-carboxamide cycloamino urea derivatives in the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013009624A2 true BR112013009624A2 (pt) | 2016-07-12 |
Family
ID=44947083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013009624A BR112013009624A2 (pt) | 2010-11-08 | 2011-11-07 | uso de derivados de 2-carboxamida cicloamino ureia no tratamento de doenças dependemtes de egfr pu doenças que tenham adquirido resistência a agentes que tenham como alvo membros da família egfr |
Country Status (12)
Country | Link |
---|---|
US (4) | US20130209461A1 (pt) |
EP (1) | EP2637661B1 (pt) |
JP (4) | JP2013542228A (pt) |
KR (1) | KR101854484B1 (pt) |
CN (2) | CN103200943A (pt) |
AU (1) | AU2011328227B2 (pt) |
BR (1) | BR112013009624A2 (pt) |
CA (1) | CA2815492C (pt) |
MX (1) | MX360157B (pt) |
RU (1) | RU2589695C2 (pt) |
TR (1) | TR201802943T4 (pt) |
WO (1) | WO2012062694A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2624493C2 (ru) * | 2011-10-14 | 2017-07-04 | Новартис Аг | 2-КАРБОКСАМИД ЦИКЛОАМИНО ПРОИЗВОДНЫЕ МОЧЕВИНЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ Hsp90 ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ |
US20140302022A1 (en) * | 2011-11-02 | 2014-10-09 | Novartis Ag | 2-carboxamide clycloamino urea derivatives for use in treating vegf-dependent diseases |
CN104519887B (zh) * | 2012-08-07 | 2017-06-27 | 诺华股份有限公司 | 包含B‑Raf抑制剂、EGFR抑制剂和任选PI3Kα抑制剂的药物组合 |
JP2015529194A (ja) * | 2012-08-16 | 2015-10-05 | ノバルティス アーゲー | PI3Kインヒビターとc−Metインヒビターの組み合わせ |
CN105163736A (zh) * | 2013-04-05 | 2015-12-16 | 赛诺菲 | 包含PI3Kβ选择性抑制剂和PI3Kα选择性抑制剂的抗肿瘤组合物 |
DK3076969T3 (da) * | 2013-12-06 | 2021-11-22 | Novartis Ag | Doseringsregime for en alfa-isoform-selektiv phosphatidylinositol-3-kinase-hæmmer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
TW200519106A (en) * | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
US8940771B2 (en) * | 2007-12-20 | 2015-01-27 | Novartis Ag | Organic compounds |
ES2545977T3 (es) * | 2008-03-18 | 2015-09-17 | Genentech, Inc. | Combinaciones de un conjugado de anticuerpo-fármaco anti-HER2 y agentes quimioterapéuticos, y métodos de uso |
UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
-
2011
- 2011-11-07 US US13/879,644 patent/US20130209461A1/en not_active Abandoned
- 2011-11-07 AU AU2011328227A patent/AU2011328227B2/en active Active
- 2011-11-07 TR TR2018/02943T patent/TR201802943T4/tr unknown
- 2011-11-07 JP JP2013537156A patent/JP2013542228A/ja active Pending
- 2011-11-07 MX MX2013005182A patent/MX360157B/es active IP Right Grant
- 2011-11-07 BR BR112013009624A patent/BR112013009624A2/pt not_active IP Right Cessation
- 2011-11-07 CA CA2815492A patent/CA2815492C/en active Active
- 2011-11-07 CN CN2011800538729A patent/CN103200943A/zh active Pending
- 2011-11-07 WO PCT/EP2011/069522 patent/WO2012062694A1/en active Application Filing
- 2011-11-07 KR KR1020137011803A patent/KR101854484B1/ko active IP Right Grant
- 2011-11-07 RU RU2013126485/15A patent/RU2589695C2/ru active
- 2011-11-07 EP EP11782111.6A patent/EP2637661B1/en active Active
- 2011-11-07 CN CN201510770643.9A patent/CN105412105A/zh active Pending
-
2015
- 2015-05-26 US US14/721,064 patent/US20150250778A1/en not_active Abandoned
-
2016
- 2016-07-07 JP JP2016134705A patent/JP2016222686A/ja not_active Withdrawn
-
2018
- 2018-07-12 US US16/033,764 patent/US20180325883A1/en not_active Abandoned
- 2018-10-24 JP JP2018199647A patent/JP2019048822A/ja not_active Withdrawn
-
2019
- 2019-09-17 US US16/573,909 patent/US20200022967A1/en not_active Abandoned
-
2020
- 2020-03-26 JP JP2020056250A patent/JP2020114849A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2815492A1 (en) | 2012-05-18 |
AU2011328227A1 (en) | 2013-04-18 |
RU2589695C2 (ru) | 2016-07-10 |
JP2020114849A (ja) | 2020-07-30 |
KR101854484B1 (ko) | 2018-05-03 |
JP2013542228A (ja) | 2013-11-21 |
JP2016222686A (ja) | 2016-12-28 |
TR201802943T4 (tr) | 2018-03-21 |
MX360157B (es) | 2018-10-24 |
CN103200943A (zh) | 2013-07-10 |
CN105412105A (zh) | 2016-03-23 |
MX2013005182A (es) | 2013-07-03 |
US20130209461A1 (en) | 2013-08-15 |
CA2815492C (en) | 2019-04-09 |
EP2637661A1 (en) | 2013-09-18 |
US20150250778A1 (en) | 2015-09-10 |
US20180325883A1 (en) | 2018-11-15 |
RU2013126485A (ru) | 2014-12-20 |
KR20130143582A (ko) | 2013-12-31 |
WO2012062694A1 (en) | 2012-05-18 |
JP2019048822A (ja) | 2019-03-28 |
EP2637661B1 (en) | 2017-12-20 |
AU2011328227B2 (en) | 2015-04-09 |
US20200022967A1 (en) | 2020-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013009624A2 (pt) | uso de derivados de 2-carboxamida cicloamino ureia no tratamento de doenças dependemtes de egfr pu doenças que tenham adquirido resistência a agentes que tenham como alvo membros da família egfr | |
MX2010009743A (es) | Uso de derivados de pirimidina para el tratamiento de las enfermedades dependientes de los receptores del factor de crecimiento epidermico (egfr) o de enfermedades que hayan adquirido resistencia a los agentes que se dirigen a los miembros de la fami | |
BR112015000776A2 (pt) | Agentes de ligação à rspo3 e usos dos mesmos | |
UY33396A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
BRPI0923231B1 (pt) | anticorpo anti-cmet, composição que compreende, e usos do anticorpo e da composição. | |
BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
CR20110270A (es) | Piriloxi-indoles Inhibidores del VEGF-R2 y Uso de los Mismos para el Tratamiento de Enfermedades | |
BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
BR112013027119A2 (pt) | novos conjugados ligante-droga (adcs) e uso dos mesmos | |
BR112013015498A2 (pt) | formulação localizada tópica, uso da formulação, e, método para tratamento ou profilaxia de infestação de parasita de um animal | |
BR112013007681A2 (pt) | uso terapêutico de um agonista trl e terapia de combinação | |
EA200802204A1 (ru) | Применение ингибиторов dpp iv | |
BR112013015503A2 (pt) | formulação localizada tópica, uso de uma formulação, e, método para tratamento ou profilaxia de infestação de parasita de um animal | |
BR112012022552A8 (pt) | uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos | |
BR112014006587A8 (pt) | Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes | |
BR112012006010A2 (pt) | composto de glicina | |
BR112012027545A2 (pt) | composto de fórmula i, composição farmacêutica, uso da composição farmacêutica, uso de um composto e método de modulação do nível de glicose no sangue em um indivíduo | |
BR112014011868A2 (pt) | composições corantes poliméricas e métodos de uso | |
BR112017026535A2 (pt) | composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto | |
BR112015006656A8 (pt) | composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos | |
BR112015014532A2 (pt) | composições cosméticas de fluido de eclosão de peixe | |
BR112013010136A2 (pt) | vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma | |
GT201700220A (es) | Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap) | |
BR112015019873A2 (pt) | inibidores macrocíclicos da lrrk2 cinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2643 DE 31-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |